Literature DB >> 24933320

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9.

Joanna Nikitorowicz-Buniak1, Xu Shiwen2, Christopher P Denton2, David Abraham2, Richard Stratton2.   

Abstract

Skin involvement with dermal fibrosis is a hallmark of systemic sclerosis (SSc), and keratinocytes may be critical regulators of fibroblast function through secretion of chemo-attracting agents, as well as through growth factors and cytokines influencing the phenotype and proliferation rate of fibroblasts. Epithelial-fibroblast interactions have an important role in fibrosis in general. We have characterized the SSc epidermis and asked whether SSc-injured epidermal cells release factors capable of promoting fibrosis. Our results show that the SSc epidermis is hypertrophic, and has altered expression of terminal differentiation markers involucrin, loricrin, and filaggrin. Multiplex profiling revealed that SSc epidermal explants release increased levels of CCN2 and S100A9. CCN2 induction was found to spread into the upper papillary dermis, whereas S100A9 was shown to induce fibroblast proliferation and to enhance fibroblast CCN2 expression via Toll-like receptor 4. These data suggest that the SSc epidermis provides an important source of pro-fibrotic CCN2 and proinflammatory S100A9 in SSc skin, and therefore contributes to the fibrosis and inflammation seen in the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24933320     DOI: 10.1038/jid.2014.253

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  61 in total

1.  Regulation of fibroblast gene expression by keratinocytes in organotypic skin culture provides possible mechanisms for the antifibrotic effect of reepithelialization.

Authors:  Anita Koskela; Kristina Engström; Malin Hakelius; Daniel Nowinski; Mikael Ivarsson
Journal:  Wound Repair Regen       Date:  2010-08-19       Impact factor: 3.617

2.  Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.

Authors:  Nima Aden; Anna Nuttall; Xu Shiwen; Patricia de Winter; Andrew Leask; Carol M Black; Christopher P Denton; David J Abraham; Richard J Stratton
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

3.  Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor.

Authors:  K Frazier; S Williams; D Kothapalli; H Klapper; G R Grotendorst
Journal:  J Invest Dermatol       Date:  1996-09       Impact factor: 8.551

4.  Interleukin-1-induced growth factor expression in postmitotic and resting fibroblasts.

Authors:  N Maas-Szabowski; N E Fusenig
Journal:  J Invest Dermatol       Date:  1996-12       Impact factor: 8.551

5.  Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.

Authors:  Yasushi Kawaguchi; Masayoshi Harigai; Masako Hara; Chikako Fukasawa; Kae Takagi; Michi Tanaka; Eiichi Tanaka; Emi Nishimagi; Naoyuki Kamatani
Journal:  J Rheumatol       Date:  2002-09       Impact factor: 4.666

Review 6.  Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis.

Authors:  Xu Shi-Wen; Andrew Leask; David Abraham
Journal:  Cytokine Growth Factor Rev       Date:  2008-04       Impact factor: 7.638

7.  Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes.

Authors:  Pierre Shephard; Boris Hinz; Sigrun Smola-Hess; Jean-Jacques Meister; Thomas Krieg; Hans Smola
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

8.  Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.

Authors:  Xue Xu; Wen-Yu Wu; Wen-Zheng Tu; Hai-Yan Chu; Xiao-Xia Zhu; Min-Rui Liang; Yu Xue; Jiu-Cun Wang; He-Jian Zou
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

9.  Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis.

Authors:  Christine A Davies; Ariane L Herrick; Lis Cordingley; Anthony J Freemont; Maria Jeziorska
Journal:  Rheumatology (Oxford)       Date:  2009-06-19       Impact factor: 7.580

10.  Molecular subsets in the gene expression signatures of scleroderma skin.

Authors:  Ausra Milano; Sarah A Pendergrass; Jennifer L Sargent; Lacy K George; Timothy H McCalmont; M Kari Connolly; Michael L Whitfield
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  18 in total

1.  The use of luminex assays to measure cytokines.

Authors:  Saami Khalifian; Giorgio Raimondi; Gerald Brandacher
Journal:  J Invest Dermatol       Date:  2015-04       Impact factor: 8.551

Review 2.  Calprotectin in rheumatic diseases.

Authors:  Francesca Ometto; Lara Friso; Davide Astorri; Costantino Botsios; Bernd Raffeiner; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-01

Review 3.  The Immunogenetics of Morphea and Lichen Sclerosus.

Authors:  Pooya Khan Mohammad Beigi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  What can we learn from Fli1-deficient mice, new animal models of systemic sclerosis?

Authors:  Yoshihide Asano
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

5.  Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.

Authors:  Sara S McCoy; Tamra J Reed; Celine C Berthier; Pei-Suen Tsou; Jianhua Liu; Johann E Gudjonsson; Dinesh Khanna; J Michelle Kahlenberg
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

6.  Calprotectin, an available prognostic biomarker in systemic sclerosis: a systematic review.

Authors:  Bahareh Ebrahimi; MohamadAli Nazarinia; Mina Molayem
Journal:  Clin Rheumatol       Date:  2020-10-12       Impact factor: 2.980

7.  Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma.

Authors:  Xingyu Zhu; Liuyiqi Jiang; Qian Zhong; Xiangzhen Kong; Rui Zhang; Lingxian Zhu; Qingmei Liu; Wenyu Wu; Yimei Tan; Jiucun Wang; Jingjing Xia
Journal:  Clin Rheumatol       Date:  2022-03-12       Impact factor: 2.980

8.  A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.

Authors:  Xu Shiwen; Richard Stratton; Joanna Nikitorowicz-Buniak; Bahja Ahmed-Abdi; Markella Ponticos; Christopher Denton; David Abraham; Ayuko Takahashi; Bela Suki; Matthew D Layne; Robert Lafyatis; Barbara D Smith
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 9.  Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.

Authors:  Alsya J Affandi; Timothy R D J Radstake; Wioleta Marut
Journal:  Semin Immunopathol       Date:  2015-07-14       Impact factor: 9.623

10.  Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma Skin.

Authors:  Joanna Nikitorowicz-Buniak; Christopher P Denton; David Abraham; Richard Stratton
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.